Status:

UNKNOWN

Effectiveness of Once-daily Dose Regimen of 7-day and 14-day High Dose Rabeprazole-levofloxacin Based Quadruple Therapy for H. Pylori Eradication in Thai Patients With Non-ulcer Dyspepsia

Lead Sponsor:

Thammasat University

Conditions:

Helicobacter Pylori Infection

Eligibility:

All Genders

18-70 years

Phase:

PHASE1

Brief Summary

H.pylori is an organism which causes gastric inflammation, peptic ulcer disease (PUD), mucosa associated lymphoid tissue (MALT) lymphoma and gastric cancer. Practical guideline for treatment of patie...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Thai patients with the age between 18 and 70 years
  • Detecting for H.pylori infection with positive urease test and/or pathological findings of H.pylori and/or positive
  • Exclusion criteria:
  • Any cases with upper gastrointestinal bleeding
  • Being treated with medications affecting the research outcome, for example, by using antibiotics including amoxicillin, clarithromycin, metronidazole or fluoroquinolone within 1 month before the enrollment.
  • Contraindicated for gastric biopsy such as coagulopathy.
  • Any history of drug allergy for levofloxacin, clarithromycin or rabeprazole.
  • Receiving proton pump inhibitor within 4 weeks or receiving any antibiotics or bismuth within 2 weeks.
  • Being pregnant or raising children with lactation.
  • Having history of H.pylori eradication treatment.
  • Having severe underlying disease including end-stage renal disease requiring hemodialysis or peritoneal dialysis (GFR \< 15), cirrhosis with Child-Pugh classification grade C, immunocompromised host with AIDS, malignancy and/or bed ridden cerebrovascular disease.
  • Any cases who receiving anticoagulant.
  • Having previous gastric surgery.
  • Unwilling to participate into research.
  • Having history of taking previous medications which interacted with the research treatment.
  • Having underlying heart disease including congenital long QT syndrome.

Exclusion

    Key Trial Info

    Start Date :

    May 15 2017

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    May 15 2018

    Estimated Enrollment :

    100 Patients enrolled

    Trial Details

    Trial ID

    NCT03397680

    Start Date

    May 15 2017

    End Date

    May 15 2018

    Last Update

    May 1 2018

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Thammasat University Hospital

    Khlong Luang, Patumthanee, Thailand, 12121

    Effectiveness of Once-daily Dose Regimen of 7-day and 14-day High Dose Rabeprazole-levofloxacin Based Quadruple Therapy for H. Pylori Eradication in Thai Patients With Non-ulcer Dyspepsia | DecenTrialz